<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="cam470541" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Med</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Med</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2045-7634</journal-id><journal-id journal-id-type="publisher-id">CAM4</journal-id><journal-title-group><journal-title>Cancer Medicine</journal-title></journal-title-group><issn pub-type="epub">2045-7634</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39891416</article-id><article-id pub-id-type="pmc">PMC11785910</article-id><article-id pub-id-type="doi">10.1002/cam4.70541</article-id><article-id pub-id-type="publisher-id">CAM470541</article-id><article-id pub-id-type="other">CAM4-2024-03-1640.R4</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Haploidentical Stem Cell Transplantation With Dual Source of Cells and Post&#x02010;Transplant Cyclophosphamide</article-title></title-group><contrib-group><contrib id="cam470541-cr-0001" contrib-type="author" corresp="yes"><name><surname>Fonseca&#x02010;Hial</surname><given-names>Ana Marcela Rojas</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6683-3836</contrib-id><xref rid="cam470541-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cam470541-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>amarcela@terra.com.br</email></address></contrib><contrib id="cam470541-cr-0002" contrib-type="author"><name><surname>Parisio</surname><given-names>Katya</given-names></name><xref rid="cam470541-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cam470541-cr-0003" contrib-type="author"><name><surname>de Oliveira</surname><given-names>Jose Salvador Rodrigues</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9862-4345</contrib-id><xref rid="cam470541-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cam470541-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="cam470541-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Transplante de Medula Ossea Section</named-content>
<institution>Federal University of Sao Paulo&#x02014;UNIFESP</institution>
<city>Sao Paulo</city>
<country country="BR">Brazil</country>
</aff><aff id="cam470541-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Transplante de Medula Ossea Section</named-content>
<institution>Hospital Santa Marcelina</institution>
<city>Sao Paulo</city>
<country country="BR">Brazil</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Ana Marcela Rojas Fonseca&#x02010;Hial (<email>amarcela@terra.com.br</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>14</volume><issue seq="580">3</issue><issue-id pub-id-type="doi">10.1002/cam4.v14.3</issue-id><elocation-id>e70541</elocation-id><history>
<date date-type="rev-recd"><day>09</day><month>12</month><year>2024</year></date>
<date date-type="received"><day>22</day><month>3</month><year>2024</year></date>
<date date-type="accepted"><day>15</day><month>12</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 Published by John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Cancer Medicine</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:CAM4-14-e70541.pdf"/><abstract><title>ABSTRACT</title><sec id="cam470541-sec-1001"><title>Background</title><p>Dual sources of cells (DSC) with peripheral blood stem cell apheresis (PBSC) and surgical bone marrow (BM) for haploidentical hematopoietic cell transplantation (Hid&#x02010;HCT) are used in China and some Asian countries. The experience of the Baltimore group for haploidentical transplant with post&#x02010;transplant cyclophosphamide (PT&#x02010;Cy) and reduced&#x02010;intensity&#x02010;conditioning (RIC) regimen used BM as a source of hematopoietic stem cells.</p></sec><sec id="cam470541-sec-1002"><title>Methods</title><p>We retrospectively analyzed 64 Hid&#x02010;HCT with DSC and PT&#x02010;Cy, RIC (<italic toggle="no">n</italic>&#x02009;=&#x02009;57), or myeloablative&#x02010;conditioning (MAC) (<italic toggle="no">n</italic>&#x02009;=&#x02009;7), from two public health Brazilian centers, with a median follow&#x02010;up of 23.3&#x02009;months (6.7&#x02013;45.4).</p></sec><sec id="cam470541-sec-1003"><title>Results</title><p>The 49 malignant patients were 27/46 (58.7%) beyond the first remission or with no complete response, and three patients did not complete disease status evaluation before transplant. Eight of 62 patients (12.9%) had grade 2 or more Hematopoietic Cell Transplantation&#x02010;Specific Comorbidity Index (HCT&#x02010;CI), and two patients had no HCT&#x02010;CI classified. Cytomegalovirus (CMV) viremia occurred in 26 of 57 (45.6%). The cumulative incidence of 100&#x02010;day grade III&#x02010;IV acute GVHD was 12.3% (7/57), with a 95% confidence interval (CI) of 3.8% and 20.8%, and 2&#x02010;year moderate or severe chronic GVHD was 21.1% (11/52; 95% CI, 10.1%&#x02013;32.3%). The 2&#x02010;year relapses were 24.5% for malignant disease (12/49; 95% CI, 12.4%&#x02013;36.5%). The 2&#x02010;year overall survival (OS) probability was 54.7% (35/64; 95% CI, 42.5%&#x02013;66.9%). Benign diseases achieve 2&#x02010;year OS in 73.3% (11/15; 95% CI, 51%&#x02013;95.7%) of the patients. The HCT&#x02010;CI were significant in multivariate analyses for DFS (<italic toggle="no">p</italic>&#x02009;=&#x02009;0.002) and OS in uni&#x02010; and multivariate analyses (both <italic toggle="no">p</italic>&#x02009;&#x0003c;&#x02009;0.001). The number of CD34<sup>+</sup> cells by apheresis collection was significant in multivariate analysis for DFS (<italic toggle="no">p</italic>&#x02009;=&#x02009;0.039).</p></sec><sec id="cam470541-sec-1004"><title>Conclusion</title><p>Hid&#x02010;HCT using PT&#x02010;Cy, DSC, and RIC is a safe option for benign and malignant diseases.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cam470541-kwd-0001">allogeneic</kwd><kwd id="cam470541-kwd-0002">dual source of cells</kwd><kwd id="cam470541-kwd-0003">haploidentical</kwd><kwd id="cam470541-kwd-0004">post&#x02010;transplant cyclophosphamide</kwd><kwd id="cam470541-kwd-0005">reduced intensity conditioning</kwd></kwd-group><counts><fig-count count="2"/><table-count count="6"/><page-count count="12"/><word-count count="7200"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.3 mode:remove_FC converted:01.02.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="cam470541-ntgp-0001"><fn fn-type="funding" id="cam470541-note-0001"><p>
<bold>Funding:</bold> The authors received no specific funding for this work.</p></fn></fn-group></notes></front><body id="cam470541-body-0001"><def-list list-content="abbreviations" id="cam470541-dl-0001"><title>Abbreviations</title><def-item><term id="cam470541-li-0001">ALL</term><def id="cam470541-li-0002"><p>acute lymphoblastic leukemia</p></def></def-item><def-item><term id="cam470541-li-0003">AML</term><def id="cam470541-li-0004"><p>acute myeloid leukemia</p></def></def-item><def-item><term id="cam470541-li-0005">ATG</term><def id="cam470541-li-0006"><p>antithymocyte globulin</p></def></def-item><def-item><term id="cam470541-li-0007">BM</term><def id="cam470541-li-0008"><p>surgical bone marrow</p></def></def-item><def-item><term id="cam470541-li-0009">CML</term><def id="cam470541-li-0010"><p>chronic myeloid leukemia</p></def></def-item><def-item><term id="cam470541-li-0011">CMV</term><def id="cam470541-li-0012"><p>cytomegalovirus</p></def></def-item><def-item><term id="cam470541-li-0013">CR1</term><def id="cam470541-li-0014"><p>first complete remission</p></def></def-item><def-item><term id="cam470541-li-0015">CR2</term><def id="cam470541-li-0016"><p>second complete remission</p></def></def-item><def-item><term id="cam470541-li-0017">CRGNB</term><def id="cam470541-li-0018"><p>carbapenem&#x02010;resistant gram&#x02010;negative bacilli</p></def></def-item><def-item><term id="cam470541-li-0019">DSA</term><def id="cam470541-li-0020"><p>HLA donor specific antibodies</p></def></def-item><def-item><term id="cam470541-li-0021">DSC</term><def id="cam470541-li-0022"><p>dual source of cells</p></def></def-item><def-item><term id="cam470541-li-0023">DFS</term><def id="cam470541-li-0024"><p>disease free survival</p></def></def-item><def-item><term id="cam470541-li-0025">G&#x02010;CSF</term><def id="cam470541-li-0026"><p>granulocyte&#x02010;colony stimulating factor</p></def></def-item><def-item><term id="cam470541-li-0027">GvHD</term><def id="cam470541-li-0028"><p>graft&#x02010;versus&#x02010;host disease</p></def></def-item><def-item><term id="cam470541-li-0029">HCT</term><def id="cam470541-li-0030"><p>hematopoietic cells transplantation</p></def></def-item><def-item><term id="cam470541-li-0031">HCT&#x02010;CI</term><def id="cam470541-li-0032"><p>hematopoietic cell transplantation&#x02010;specific comorbidity index</p></def></def-item><def-item><term id="cam470541-li-0033">Hid&#x02010;HCT</term><def id="cam470541-li-0034"><p>haploidentical hematopoietic cells transplantation</p></def></def-item><def-item><term id="cam470541-li-0035">IRM</term><def id="cam470541-li-0036"><p>infection related mortality</p></def></def-item><def-item><term id="cam470541-li-0037">KPC</term><def id="cam470541-li-0038"><p>Klebsiella pneumoniae carbapenemases</p></def></def-item><def-item><term id="cam470541-li-0039">LFS</term><def id="cam470541-li-0040"><p>leukemia&#x02010;free survival</p></def></def-item><def-item><term id="cam470541-li-0041">MAC</term><def id="cam470541-li-0042"><p>myeloablative conditioning</p></def></def-item><def-item><term id="cam470541-li-0043">MDS</term><def id="cam470541-li-0044"><p>myelodysplasic syndromes</p></def></def-item><def-item><term id="cam470541-li-0045">MRD</term><def id="cam470541-li-0046"><p>minimal residual disease</p></def></def-item><def-item><term id="cam470541-li-0047">NRM</term><def id="cam470541-li-0048"><p>non&#x02010;relapse mortality</p></def></def-item><def-item><term id="cam470541-li-0049">OS</term><def id="cam470541-li-0050"><p>overall survival</p></def></def-item><def-item><term id="cam470541-li-0051">PBSC</term><def id="cam470541-li-0052"><p>peripheral blood stem cell</p></def></def-item><def-item><term id="cam470541-li-0053">PT&#x02010;Cy</term><def id="cam470541-li-0054"><p>post&#x02010;transplant cyclophosphamide</p></def></def-item><def-item><term id="cam470541-li-0055">SAA</term><def id="cam470541-li-0056"><p>severe aplastic anemia</p></def></def-item><def-item><term id="cam470541-li-0057">TBI</term><def id="cam470541-li-0058"><p>total body irradiation</p></def></def-item><def-item><term id="cam470541-li-0059">TNC</term><def id="cam470541-li-0060"><p>total nucleated cells</p></def></def-item><def-item><term id="cam470541-li-0061">VOD/SOS</term><def id="cam470541-li-0062"><p>veno&#x02010;occlusive disease/sinusoidal obstruction syndrome</p></def></def-item><def-item><term id="cam470541-li-0063">VRE</term><def id="cam470541-li-0064"><p>Vancomycin&#x02010;resistant enterococci</p></def></def-item></def-list><sec id="cam470541-sec-0001"><label>1</label><title>Introduction</title><p>Hid&#x02010;HCT has increased since 2012, overcoming the number of matched HLA&#x02010;identical HCT since 2020 [<xref rid="cam470541-bib-0001" ref-type="bibr">1</xref>]. In 2020, the Center for International Blood and Marrow Transplant Research (CIBMTR) reported that 72% of Hid&#x02010;HCT was from PBSC, the remaining from BM. In China, 99% of Hid&#x02010;HCT follow the Beijing Protocol: (1) granulocyte&#x02010;colony stimulating factor for all donors (G&#x02010;CSF); (2) intensive immune suppression; (3) anti&#x02010;human thymocyte immunoglobulin (ATG) for GVHD prophylaxis; and (4) the combination of G&#x02010;CSF primed PBSC and BM as hematopoietic stem cells sources [<xref rid="cam470541-bib-0002" ref-type="bibr">2</xref>, <xref rid="cam470541-bib-0003" ref-type="bibr">3</xref>].</p><p>Zhao et&#x000a0;al. in 2016 [<xref rid="cam470541-bib-0004" ref-type="bibr">4</xref>] compared Hid&#x02010;HCT with PBSC (<italic toggle="yes">n</italic>&#x02009;=&#x02009;42) versus DSC (<italic toggle="yes">n</italic>&#x02009;=&#x02009;168) in malignant disease beyond the first remission, using ATG for GVHD prophylaxis. There are no differences in non&#x02010;relapse mortality (NRM), relapse, engraftment, or acute and chronic GVHD, but a better 3&#x02010;year DFS and OS were disclosed for DSC, 59.9% versus 44.3% and 65% versus 54.2%, respectively. Wang et&#x000a0;al. in 2015 [<xref rid="cam470541-bib-0005" ref-type="bibr">5</xref>] used the Beijing protocol with MAC and ATG for GVHD prophylaxis in 450 AML patients, Hid&#x02010;HCT (<italic toggle="yes">n</italic>&#x02009;=&#x02009;231) or identical sibling transplants (<italic toggle="yes">n</italic>&#x02009;=&#x02009;219). They disclosed similar results for OS, relapse, DFS, and NRM.</p><p>Luznik et&#x000a0;al. in 2008 [<xref rid="cam470541-bib-0006" ref-type="bibr">6</xref>] evaluated the high&#x02010;dose PT&#x02010;Cy in Hid&#x02010;HCT to prevent engraftment rejection and GVHD. Engraftment rejection occurred in 13% of patients. The median neutrophil engraftment was 15&#x02009;days. The Grades II&#x02013;IV and III&#x02013;IV acute GVHD by D&#x02009;+&#x02009;200 were 34% and 6%, respectively. Extensive chronic GVHD at 1&#x02009;year was 5% for two doses of 50&#x02009;mg/kg and 25% for one dose (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.05%). The probabilities of NRM at D&#x02009;+&#x02009;100 and 1&#x02009;year were 4% and 15%, and relapse was 51% and 58% for one or two doses (NS). OS and DFS were not statistically significant. This publication was the first one to enable the spread of Hid&#x02010;HSC elsewhere.</p><p>Bashey et&#x000a0;al. evaluated 681 patients with hematologic malignancy who underwent haploidentical transplantation with PT&#x02010;Cy in the United States between 2009 and 2014 and received BM (<italic toggle="yes">n</italic>&#x02009;=&#x02009;481) or PB (<italic toggle="yes">n</italic>&#x02009;=&#x02009;190) grafts. Hematopoietic recovery was similar between BM and PB transplantations (28&#x02010;day neutrophil recovery, 88% vs. 93%, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.07; 100&#x02010;day platelet recovery, 88% vs. 85%, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.33). Risks of Grades 2&#x02013;4 acute (hazard ratio [HR], 0.45; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.001) and chronic (HR, 0.35; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.001) graft&#x02010;versus&#x02010;host diseases in BM transplantations were lower than PB transplantations. There were no significant differences in overall survival by graft type (HR, 0.99; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.98), with rates of 54% and 57% at 2 years after transplantation of BM and PB, respectively. There were no differences in non&#x02010;relapse mortality risks (HR, 0.92; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.74), but relapse risks were higher after transplantation of BM (HR, 1.49; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.009). Additional exploration confirmed that the higher relapse risk after the transplantation of BM was limited to patients with leukemia (HR, 1.73; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.002) but not lymphoma (HR, 0.87; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.64) [<xref rid="cam470541-bib-0007" ref-type="bibr">7</xref>].</p><p>The purpose of this study was to retrospectively analyze the results of the association of DSC based on Chinese experience and GVHD prophylaxis with PT&#x02010;Cy designed for Baltimore Protocol in two Brazilian centers. DSC in these institutions has been adopted since 2013 to achieve earlier engraftment, shorter hospitalization time, and fewer engraftment failures, despite the possibility of a higher incidence of acute and chronic GVHD. Due to the frailty of the assisted population, the priority was to perform RIC, leaving MAC only for patients with very advanced diseases.</p></sec><sec sec-type="methods" id="cam470541-sec-0002"><label>2</label><title>Methods</title><sec id="cam470541-sec-0003"><label>2.1</label><title>Study Design</title><p>We analyzed 64 Hid&#x02010;HCT in two public hospitals in Brazil, Hospital Santa Marcelina and Hospital S&#x000e3;o Paulo UNIFESP, from July 2016 to October 2019. All patients who underwent Hid&#x02010;HCT with DSC in this period were invited to participate, and their medical records were reviewed. The ethics committees of these two institutions approved this study.</p></sec><sec id="cam470541-sec-0004"><label>2.2</label><title>Conditioning Regimens</title><p>The conditioning most used for the Hid&#x02010;HCT was RIC, the Baltimore protocol [<xref rid="cam470541-bib-0006" ref-type="bibr">6</xref>]. This conditioning consists of fludarabine 30&#x02009;mg/m<sup>2</sup>/day i.v. on Days &#x02212;6 to &#x02212;2, cyclophosphamide 14.5&#x02009;mg/kg/day i.v. on Days &#x02212;6 and &#x02212;5, total&#x02010;body irradiation (TBI) 200&#x02009;cGy, associated with PT&#x02010;Cy. The post&#x02010;transplant cyclophosphamide was applied on D&#x02009;+&#x02009;3 and D&#x02009;+&#x02009;4 at 50&#x02009;mg/kg/day. In patients with hemoglobinopathies, thymoglobulin was associated with the conditioning, 5&#x02009;mg/kg divided over 4&#x02009;days until D&#x02010;1 [<xref rid="cam470541-bib-0008" ref-type="bibr">8</xref>]. The CSA was initiated on D&#x02009;+&#x02009;5 at 2&#x02009;mg/kg/day i.v., adjusted to achieve a therapeutic level of 100&#x02013;300&#x02009;ng/mL, and converted to oral form until discontinuation. If there was no active GVHD, CSA was tapered at D&#x02009;+&#x02009;60 and discontinued at D&#x02009;+&#x02009;120, except for benign diseases. Mycophenolate mofetil (MMF) was prescribed on D&#x02009;+&#x02009;5 to D&#x02009;+&#x02009;35, at a dose of 15&#x02009;mg/kg three times daily.</p><p>Surveillance and GVHD were assessed thrice a week until D&#x02009;+&#x02009;60 and twice a week until D&#x02009;+&#x02009;100. Then, every 2 or 4&#x02009;weeks, depending on progress. Blood cultures for infection were taken whenever patients had a fever or other signs of disease.</p></sec><sec id="cam470541-sec-0005"><label>2.3</label><title>
<styled-content style="fixed-case" toggle="no">PBSC</styled-content> Mobilization and Collection</title><p>Donors were primed with G&#x02010;CSF, 5&#x02013;10 mcg/kg/day for four or five consecutive days. On the fourth day, PBSCs were collected with a COBE Blood Cell Separator (Spectra LRS, COBE BCT Inc., Lakewood, CO, USA). The target of PBSC to be infused were 5&#x02013;10&#x02009;&#x000d7;&#x02009;10<sup>6</sup> cells/kg recipient weight. On the fifth day, bone marrow cells were harvested. The target total nucleated cell count (TNC) was 3&#x02013;4&#x02009;&#x000d7;&#x02009;10<sup>8</sup> cells/kg recipient weight. The fresh and unmanipulated bone marrow and PBSCs were infused on the day of surgical collection [<xref rid="cam470541-bib-0002" ref-type="bibr">2</xref>].</p></sec><sec id="cam470541-sec-0006"><label>2.4</label><title>Antimicrobial Prophylaxis and Follow&#x02010;Up</title><p>Patients were admitted to HEPA&#x02010;filtered units and underwent anal swab examination to investigate colonization by multidrug&#x02010;resistant bacteria and CRGNB. Antimicrobial prophylaxis using ciprofloxacin, trimethoprim&#x02010;sulfamethoxazole, acyclovir, and fluconazole began at admission [<xref rid="cam470541-bib-0009" ref-type="bibr">9</xref>, <xref rid="cam470541-bib-0010" ref-type="bibr">10</xref>, <xref rid="cam470541-bib-0011" ref-type="bibr">11</xref>, <xref rid="cam470541-bib-0012" ref-type="bibr">12</xref>]. This prophylaxis was maintained until the end of immunosuppression.</p><p>After engraftment, all patients were monitored for CMV infection with plasmatic DNA polymerase chain reaction (PCR) twice a week until Day 60, then once a week. Above 10,000 copies/mL, or a progressive increase, the preventive use of intravenous ganciclovir was started, up to two consecutive exams with a below 10,000/mL copies.</p></sec><sec id="cam470541-sec-0007"><label>2.5</label><title>Statistical Analysis</title><p>The absolute and relative frequencies were calculated for the categorical variables; for numerical variables, the mean and standard derivation; and for the mean comparisons between more than two variables, the analysis of variance was performed. The normality determination in the variance distribution data was verified with the Kolmogorov&#x02013;Smirnov test. Overall survival was defined as the time from HCT until the last medical appointment or death. Relapse was defined as the return of the malignant disease. Non&#x02010;relapse mortality (NRM) was characterized as death without evidence of relapse. Acute and chronic GVHD were determined as a reaction of donor immune cells against host tissues. The disease&#x02010;free survival (DFS) was defined as the time to the first event of relapse, death, or last medical appointment. Relapse, GVHD outcomes, and NRM have been calculated using the cumulative incidence function. Relapse incidence (RI) and NRM were mutually competing events. Death was a competing event of GVHD outcomes. Survival analyses were based on the Kaplan&#x02013;Meier model and the effect of covariates on survival was based on the Cox model. Survival functions were estimated for each level of these variables and then compared using the Log Rank test (Mantel&#x02013;Cox). In addition, univariate Cox models were fitted for all predictor variables, followed by a multivariate model. The significance level was set at 5%. Statistical analyses were performed using SPSS 20.0 and STATA 17 statistical software.</p></sec></sec><sec sec-type="results" id="cam470541-sec-0008"><label>3</label><title>Results</title><p>From July 2016 to October 2019, there were 64 Hid&#x02010;HCT with DSC and PT&#x02010;Cy, Table&#x000a0;<xref rid="cam470541-tbl-0001" ref-type="table">1</xref>. Malignant diseases were considered with advanced disease in 27/46 (58.7%), and three patients did not complete disease status evaluation before transplant. MRD was positive in 6/29 (20.7%) of acute leukemias, all lymphomas were in partial or worse response, and all cases of CML were refractory to 2nd&#x02010;generation TKI. Low, intermediate, high, and very high disease risk index (DRI) [<xref rid="cam470541-bib-0013" ref-type="bibr">13</xref>] were 2&#x02010;year OS 75%, 40.6%, 39.1%, and 46.8%, respectively. Of the benign diseases, the 10 patients with SAA had more than 10 red blood cell transfusions and a median diagnosis of 16.3 (3.8&#x02013;164) months until Hid&#x02010;HCT. Sickle cell anemia patients had a median age of 17 [<xref rid="cam470541-bib-0014" ref-type="bibr">14</xref>, <xref rid="cam470541-bib-0015" ref-type="bibr">15</xref>, <xref rid="cam470541-bib-0016" ref-type="bibr">16</xref>, <xref rid="cam470541-bib-0017" ref-type="bibr">17</xref>, <xref rid="cam470541-bib-0018" ref-type="bibr">18</xref>, <xref rid="cam470541-bib-0019" ref-type="bibr">19</xref>, <xref rid="cam470541-bib-0020" ref-type="bibr">20</xref>, <xref rid="cam470541-bib-0021" ref-type="bibr">21</xref>, <xref rid="cam470541-bib-0022" ref-type="bibr">22</xref>, <xref rid="cam470541-bib-0023" ref-type="bibr">23</xref>, <xref rid="cam470541-bib-0024" ref-type="bibr">24</xref>] years and received multiple transfusions.</p><table-wrap position="float" id="cam470541-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Characteristics of patients.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Age years (range)</th><th align="center" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">26 [3&#x02013;66]</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="3" valign="top" rowspan="1">
<bold>Gender, <italic toggle="yes">N</italic>&#x000b0; (%)</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">39 (61)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">25 (39)</td></tr><tr><td align="left" colspan="3" valign="top" rowspan="1">
<bold>Diagnosis</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>MALIGN DISEASES</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">49/64 (76.5%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Acute leukemias</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">32/49</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Acute lymphocytic leukemia</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">17</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">CR1, MRD neg</td><td align="center" valign="top" rowspan="1" colspan="1">12</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">CR2, MRD neg</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">CR2 or CR3, MRD pos</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Acute Myeloid Leukemia</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">13</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">CR1, MRD neg</td><td align="center" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">CR1, MRD NA</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">CR2 or CR3, MRD neg</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">CR2 or CR3, MRD pos</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Mixed Phenotype Acute Leukemia</td><td align="center" valign="top" rowspan="1" colspan="1">CR2, MRD pos</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Dendritic Cell Leukemia</td><td align="center" valign="top" rowspan="1" colspan="1">CR1, MRD neg</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Chronic myeloid leukemia, TKI refractory</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">7/49</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Primary chronic phase</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Blast phase</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Lymphoproliferative diseases</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">9/49</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Hodgkin lymphoma</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Partial response</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Stable disease</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Progressive disease</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Non hodgkin lymphoma follicular</td><td align="center" valign="top" rowspan="1" colspan="1">Partial response</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">T&#x02010;cell prolymphocytic leukemia</td><td align="center" valign="top" rowspan="1" colspan="1">Morphologic response, MRD pos</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Myelodisplastic syndrome</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1/49</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Multilineage dysplasia</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" colspan="3" valign="top" rowspan="1">
<bold>Disease Risk Index (DRI)</bold>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Low</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">8 (16.3%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Intermediate</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">19 (38.7%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">High</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">14 (28.5%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Very high</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">8 (16.3%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>BENIGN DISEASES</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">15/64 (23%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Bone marrow failure syndromes</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">10/15</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Severe aplastic anemia</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">9</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">PNH positive</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">PNH negative</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Chronic acquired agranulocytosis</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Hereditary hemoglobinopathies</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">5/15</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Sickle cell anemia</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Sickle&#x02010;beta thalassemia</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" colspan="3" valign="top" rowspan="1">
<bold>ABO compatibility</bold>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Matched</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">45 (70.3%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Minor mismatch</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">8 (12.5%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Major mismatch</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">10 (15.6%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Bidirectional mismatch</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1 (1.5%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Donor age years (range)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">29 [12&#x02013;61]</td></tr><tr><td align="left" colspan="3" valign="top" rowspan="1">
<bold>Donor&#x02010;recipient gender match</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Female&#x02013;male</td><td align="center" valign="top" rowspan="1" colspan="1">10 (15.6%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Male&#x02013;male, female&#x02013;female</td><td align="center" valign="top" rowspan="1" colspan="1">41 (64%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Male&#x02013;female</td><td align="center" valign="top" rowspan="1" colspan="1">13 (20.3%)</td></tr><tr><td align="left" colspan="3" valign="top" rowspan="1">
<bold>Donor&#x02010;recipient relationship</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Parent&#x02013;child</td><td align="center" valign="top" rowspan="1" colspan="1">17 (26.6%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Sibling&#x02013;sibling</td><td align="center" valign="top" rowspan="1" colspan="1">35 (54.6%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Child&#x02013;parent</td><td align="center" valign="top" rowspan="1" colspan="1">12 (18.7%)</td></tr><tr><td align="left" colspan="3" valign="top" rowspan="1">
<bold>VRE and/or CRGNB colonization</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Positive</td><td align="center" valign="top" rowspan="1" colspan="1">17/54 (31.5%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Negative</td><td align="center" valign="top" rowspan="1" colspan="1">37/54 (68.5%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">10/64 (15.6%)</td></tr><tr><td align="left" colspan="3" valign="top" rowspan="1">
<bold>DSA</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Positive (MFI&#x02009;&#x0003e;&#x02009;2.000)</td><td align="center" valign="top" rowspan="1" colspan="1">3/64 (4.7%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Negative</td><td align="center" valign="top" rowspan="1" colspan="1">61/64 (95.3%)</td></tr><tr><td align="left" colspan="3" valign="top" rowspan="1">
<bold>HCT&#x02010;CI</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">31 (48.4%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">23 (36%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">5 (7.8%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x02265;&#x02009;3</td><td align="center" valign="top" rowspan="1" colspan="1">3 (4.7%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">2 (3.1%)</td></tr></tbody></table><table-wrap-foot id="cam470541-ntgp-1001"><fn id="cam470541-note-1001"><p>Abbreviations: CR1, CR2 and CR3&#x02009;=&#x02009;first, second and third complete response; CRGNB&#x02009;=&#x02009;carbapenem&#x02010;resistant gram&#x02010;negative bacilli (<styled-content style="fixed-case" toggle="no">
<italic toggle="no">Escherichia coli</italic>
</styled-content>, <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Klebsiella pneumoniae</italic>
</styled-content>, <italic toggle="yes">Pseudomonas</italic>, etc.); DSA&#x02009;=&#x02009;donor specific antibodies (HLA); MRD&#x02009;=&#x02009;minimal residual disease; NA&#x02009;=&#x02009;not available; PNH&#x02009;=&#x02009;paroxysmal nocturnal hemoglobinuria; VRE&#x02009;=&#x02009;vancomycin&#x02010;resistant enterococcus.</p></fn></table-wrap-foot></table-wrap><p>HLA donor&#x02010;specific antibodies (DSA) were negative in 61/64 (95.3%) patients, Table&#x000a0;<xref rid="cam470541-tbl-0001" ref-type="table">1</xref>. One positive AML patient with DSA DQB1 title of 6592 had engraftment failure and autologous recovery at D&#x02009;+&#x02009;34. Two other positive patients had neutrophil engraftment at D&#x02009;+&#x02009;16 and D&#x02009;+&#x02009;18. One DSA&#x02010;negative patient had engraftment failure and autologous recovery. Another engraftment failure occurred in a 27&#x02010;year&#x02010;old male SAA, who submitted the 1st Hid&#x02010;HSCT with Baltimore protocol using their mother's DSC and lost his engrafting at D&#x02009;+&#x02009;39 after a pulmonary adenovirus and JC urinary infections. Then, he performed a successful 2nd Hid&#x02010;HCT with a DSC of his cousin, but this second transplant was excluded from this casuistic. Fifty&#x02010;seven of sixty&#x02010;four patients had engrafted.</p><p>RIC was performed in 57 transplants (89%), 56 patients with Baltimore conditioning. Fludarabine and melphalan [<xref rid="cam470541-bib-0025" ref-type="bibr">25</xref>] were performed in one patient with accelerated phase CML. MAC was performed in seven transplants (10.9%). Busulfan and cyclophosphamide [<xref rid="cam470541-bib-0015" ref-type="bibr">15</xref>, <xref rid="cam470541-bib-0016" ref-type="bibr">16</xref>] were the conditioning for a CML resistant to a 2nd tyrosine kinase inhibitors (TKI) generation and in an ALL patient in the 1st negative MRD. Fludarabine and total body irradiation (TBI) 1200&#x02009;cGy [<xref rid="cam470541-bib-0017" ref-type="bibr">17</xref>, <xref rid="cam470541-bib-0018" ref-type="bibr">18</xref>] were used in two poor prognoses ALL patients. Fludarabine and busulfan [<xref rid="cam470541-bib-0019" ref-type="bibr">19</xref>] were used in chronic T&#x02010;prolymphocytic leukemia (CLL) in the 3rd morphological remission. Fludarabine, busulfan, and thiotepa [<xref rid="cam470541-bib-0018" ref-type="bibr">18</xref>, <xref rid="cam470541-bib-0020" ref-type="bibr">20</xref>] were done for a 7&#x02010;year&#x02010;old boy with ALL at 3rd morphological remission. Etoposide nanoparticles and TBI 1200&#x02009;cGy [<xref rid="cam470541-bib-0021" ref-type="bibr">21</xref>] were used in a patient with AML after MDS in 1st positive MRD with morphological remission, Table&#x000a0;<xref rid="cam470541-tbl-0002" ref-type="table">2</xref>.</p><table-wrap position="float" id="cam470541-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Transplant procedure results.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><tbody valign="top"><tr><td align="left" colspan="2" valign="top" rowspan="1">
<bold>Conditioning</bold>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">RIC</td><td align="center" valign="top" rowspan="1" colspan="1">57/64 (89%)</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">FluCyTBI</td><td align="center" valign="top" rowspan="1" colspan="1">56</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">FluMel</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">MAC</td><td align="center" valign="top" rowspan="1" colspan="1">07/64 (10.9%)</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">BuCy</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">FluTBI</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">FluBu</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">FluBuTT</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">nanoVPTBI</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">
<bold>Infused hematopoietic cells</bold>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">CD34<sup>+</sup> cells&#x02009;&#x000d7;&#x02009;10 (6)/kg (apheresis)</td><td align="center" valign="top" rowspan="1" colspan="1">7.2&#x02009;+&#x02009;&#x02212; 2.9</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">MNCs&#x02009;&#x000d7;&#x02009;10 (8)/kg (surgical harvest)</td><td align="center" valign="top" rowspan="1" colspan="1">4.8&#x02009;+&#x02009;&#x02212; 1.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Neutrophil engraftment day</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">16 [11&#x02013;34]</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Not available (death before engraftment) (7/64)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Hepatic veno&#x02010;occlusive disease</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">5/64 (7.8%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Hospital discharge</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">23 [17&#x02013;50]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Viral infection</bold>
<xref rid="cam470541-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">34/57 (59.6%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">CMV<xref rid="cam470541-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">26/57 (45.6%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Fungal infection</bold>
<xref rid="cam470541-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">7/57 (12.3%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Acute GvHD III&#x02013;IV</bold>
<xref rid="cam470541-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">7/57 (12.3%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Chronic GvHD moderate and severe</bold>
<xref rid="cam470541-note-0005" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">11/52 (21.2%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Relapse 2y</bold>
<xref rid="cam470541-note-0006" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">12/49 (24.5%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2y OS and DFS, malignant diseases</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">49% and 44.9%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2y OS, benign diseases</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">73.3%</td></tr></tbody></table><table-wrap-foot id="cam470541-ntgp-0003"><fn id="cam470541-note-0003"><p>Abbreviations: DFS&#x02009;=&#x02009;disease&#x02010;free survival, FluBu&#x02009;=&#x02009;fludarabine and busulfan, FluCyTBI&#x02009;=&#x02009;fludarabine, cyclophosphamide and total body irradiation, FluMel&#x02009;=&#x02009;fludarabine and melphalan, FluTBI&#x02009;=&#x02009;fludarabine and TBI, GvHD&#x02009;=&#x02009;graft versus host disease, MAC&#x02009;=&#x02009;myeloablative conditioning, OS&#x02009;=&#x02009;Overall survival, RIC&#x02009;=&#x02009;reduced&#x02010;intensity conditioning.</p></fn><fn id="cam470541-note-0004"><label>
<sup>a</sup>
</label><p>Evaluated in 57 patients after engraftment.</p></fn><fn id="cam470541-note-0005"><label>
<sup>b</sup>
</label><p>Evaluated in 52 patients at 100&#x02009;days after transplant.</p></fn><fn id="cam470541-note-0006"><label>
<sup>c</sup>
</label><p>Evaluated in 49 malignant diseases.</p></fn></table-wrap-foot></table-wrap><p>The number of infused PBSCs reduced the risk of disease progression. For every 1&#x02009;&#x000d7;&#x02009;10<sup>6</sup> CD34 cells/kg increase, there was a 14% reduction in disease progression by multivariate analysis (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.039).</p><p>SOS/VOD was observed in five patients (7.8%; 95% CI, 1.2%&#x02013;14.4%), Table&#x000a0;<xref rid="cam470541-tbl-0002" ref-type="table">2</xref>, all with advanced malignant diseases. Two had received myeloablative conditioning, the first died at D&#x02009;+&#x02009;48 complicated with CMV infection, and the other had mild form, recovered from this complication, and is in complete remission after 17.5&#x02009;months. Of the three patients with RIC, two relapsed and died at 10.5 and 21.6&#x02009;months, and one recovered and is alive after 29&#x02009;months.</p><p>Seven patients died before engraftment, 10.9% (95% CI, 3.3%&#x02013;18.6%) all of infection, at a median of 13.4&#x02009;days, ranging from 6 to 19. Six were previously colonized or infected. The seventh patient had a Hematopoietic Cell Transplantation&#x02010;Specific Comorbidity Index (HCT&#x02010;CI) 3 [<xref rid="cam470541-bib-0022" ref-type="bibr">22</xref>, <xref rid="cam470541-bib-0023" ref-type="bibr">23</xref>], Table&#x000a0;<xref rid="cam470541-tbl-0003" ref-type="table">3</xref>. HCT&#x02010;CI correlated with OS in univariate and multivariate analyses with <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001. For every one&#x02010;point increase in HCT&#x02010;CI, there was an 82% increase in the risk of death, Table&#x000a0;<xref rid="cam470541-tbl-0004" ref-type="table">4</xref>. The DFS for HCT&#x02010;CI was relevant only in multivariate analyses, with <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.002, Table&#x000a0;<xref rid="cam470541-tbl-0005" ref-type="table">5</xref>.</p><table-wrap position="float" id="cam470541-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Death before engraftment.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Disease</th><th align="center" valign="bottom" rowspan="1" colspan="1">Gender</th><th align="center" valign="bottom" rowspan="1" colspan="1">Age (year)</th><th align="center" valign="bottom" rowspan="1" colspan="1">HCT&#x02010;CI</th><th align="center" valign="bottom" rowspan="1" colspan="1">Previous infections</th><th align="center" valign="bottom" rowspan="1" colspan="1">Conditioning</th><th align="center" valign="bottom" rowspan="1" colspan="1">Death cause</th><th align="center" valign="bottom" rowspan="1" colspan="1">Death day</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">ALL</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="center" valign="top" rowspan="1" colspan="1">35</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">ESBL <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Escherichia coli</italic>
</styled-content> urinary, VRE axilar and inguinal swab</td><td align="center" valign="top" rowspan="1" colspan="1">FluCyTBI</td><td align="center" valign="top" rowspan="1" colspan="1">
<styled-content style="fixed-case" toggle="no">
<italic toggle="no">Pseudomonas aeruginosa</italic>
</styled-content> bloodstream; <italic toggle="yes">Fusarium oxysporum</italic> cutaneous.</td><td align="center" valign="top" rowspan="1" colspan="1">19</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HL</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="center" valign="top" rowspan="1" colspan="1">42</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">
<styled-content style="fixed-case" toggle="no">
<italic toggle="no">Pseudomonas aeruginosa</italic>
</styled-content> bronchoalveolar, and KPC anal swab</td><td align="center" valign="top" rowspan="1" colspan="1">FluCyTBI</td><td align="center" valign="top" rowspan="1" colspan="1">KPC pneumonia</td><td align="center" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AML</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="center" valign="top" rowspan="1" colspan="1">46</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">
<styled-content style="fixed-case" toggle="no">
<italic toggle="no">Pseudomonas aeruginosa</italic>
</styled-content> urinary, KPC and <italic toggle="yes">Acinetobacter baumanii</italic> anal swab</td><td align="center" valign="top" rowspan="1" colspan="1">FluCyTBI</td><td align="center" valign="top" rowspan="1" colspan="1">
<styled-content style="fixed-case" toggle="no">
<italic toggle="no">Pseudomonas aeruginosa</italic>
</styled-content> bloodstream</td><td align="center" valign="top" rowspan="1" colspan="1">15</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ALL</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="center" valign="top" rowspan="1" colspan="1">52</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">KPC and VRE anal swab</td><td align="center" valign="top" rowspan="1" colspan="1">BuCy</td><td align="center" valign="top" rowspan="1" colspan="1">KPC bloodstream</td><td align="center" valign="top" rowspan="1" colspan="1">10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SAA</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">VRE anal swab</td><td align="center" valign="top" rowspan="1" colspan="1">FluCyTBI</td><td align="center" valign="top" rowspan="1" colspan="1">
<styled-content style="fixed-case" toggle="no">
<italic toggle="no">Pseudomonas aeruginosa</italic>
</styled-content> and CMV bloodstream</td><td align="center" valign="top" rowspan="1" colspan="1">13</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CML</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="center" valign="top" rowspan="1" colspan="1">53</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">FluCyTBI</td><td align="center" valign="top" rowspan="1" colspan="1">Pulmonary sepsis</td><td align="center" valign="top" rowspan="1" colspan="1">15</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ALL</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="center" valign="top" rowspan="1" colspan="1">36</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">VRE swab anal</td><td align="center" valign="top" rowspan="1" colspan="1">FluCyTBI</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcus haemolyticus</italic> bloodstream</td><td align="center" valign="top" rowspan="1" colspan="1">16</td></tr></tbody></table><table-wrap-foot id="cam470541-ntgp-0004"><fn id="cam470541-note-0007"><p>Abbreviations: ALL&#x02009;=&#x02009;acute lymphocytic leukemia, AML&#x02009;=&#x02009;acute myeloid leukemia, CML&#x02009;=&#x02009;chronic myeloid leukemia, CML&#x02009;=&#x02009;chronic myeloid leukemia, HL&#x02009;=&#x02009;Hodgkin lymphoma, HL&#x02009;=&#x02009;Hodgkin lymphoma, KPC&#x02009;=&#x02009;<styled-content style="fixed-case" toggle="no">
<italic toggle="no">Klebsiella pneumoniae</italic>
</styled-content> carbapenemase, MRD&#x02009;=&#x02009;minimal residual disease, NA&#x02009;=&#x02009;not available, SAA&#x02009;=&#x02009;severe aplastic anemia, SAA&#x02009;=&#x02009;severe aplastic anemia, VRE&#x02009;=&#x02009;vancomycin&#x02010;resistant enterococcus.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="cam470541-tbl-0004" content-type="TABLE"><label>TABLE 4</label><caption><p>Cox regression for OS.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">4.1 Univariate</th><th align="center" valign="bottom" rowspan="1" colspan="1">Hazard ratio</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Female (reference male)</td><td align="center" valign="top" rowspan="1" colspan="1">1.57 (0.76&#x02013;3.26)</td><td align="center" valign="top" rowspan="1" colspan="1">0.226</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (years)</td><td align="center" valign="top" rowspan="1" colspan="1">1.01 (0.99&#x02013;1.03)</td><td align="center" valign="top" rowspan="1" colspan="1">0.375</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HCT&#x02010;CI</td><td align="center" valign="top" rowspan="1" colspan="1">1.89 (1.34&#x02013;2.67)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Positive surveillance swab cultures (reference negative)</td><td align="center" valign="top" rowspan="1" colspan="1">3.25 (1.53&#x02013;6.90)</td><td align="center" valign="top" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PBSC number (&#x000d7;&#x02009;10<sup>6</sup>/kg)</td><td align="center" valign="top" rowspan="1" colspan="1">0.91 (0.78&#x02013;1.06)</td><td align="center" valign="top" rowspan="1" colspan="1">0.210</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BM number (&#x000d7;10<sup>8</sup>/kg)</td><td align="center" valign="top" rowspan="1" colspan="1">0.90 (0.69&#x02013;1.17)</td><td align="center" valign="top" rowspan="1" colspan="1">0.445</td></tr></tbody></table><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="5" valign="bottom" rowspan="1">4.2 Multivariate</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1"/><th align="center" colspan="2" valign="bottom" rowspan="1">Test 1</th><th align="center" valign="bottom" rowspan="1" colspan="1">Test 2</th><th align="center" valign="bottom" rowspan="1" colspan="1"/></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Adjusted hazard ratio (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Adjusted hazard ratio (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">HCT&#x02010;CI</td><td align="center" valign="top" rowspan="1" colspan="1">1.71 (1.16&#x02013;2.53)</td><td align="center" valign="top" rowspan="1" colspan="1">0.007</td><td align="center" valign="top" rowspan="1" colspan="1">1.89 (1.34&#x02013;2.67)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Positive surveillance swab cultures (reference negative)</td><td align="center" valign="top" rowspan="1" colspan="1">1.94 (0.85&#x02013;4.41)</td><td align="center" valign="top" rowspan="1" colspan="1">0.114</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="cam470541-ntgp-0005"><fn id="cam470541-note-0008"><p>
<italic toggle="yes">Note:</italic> Proportional hazards test, test 1 chi (2)&#x02009;=&#x02009;4.44, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.109, and test 2 chi (1)&#x02009;=&#x02009;1.79, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.181.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="cam470541-tbl-0005" content-type="TABLE"><label>TABLE 5</label><caption><p>Cox regression for DFS.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">5.1 Univariate</th><th align="center" valign="bottom" rowspan="1" colspan="1">Hazard ratio (0.5)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Female (reference male)</td><td align="center" valign="top" rowspan="1" colspan="1">1.60 (0.80&#x02013;3.21)</td><td align="center" valign="top" rowspan="1" colspan="1">0.183</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (years)</td><td align="center" valign="top" rowspan="1" colspan="1">1.01 (0.99&#x02013;1.03)</td><td align="center" valign="top" rowspan="1" colspan="1">0.357</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HCT&#x02010;CI</td><td align="center" valign="top" rowspan="1" colspan="1">1.61 (1.14&#x02013;2.26)</td><td align="center" valign="top" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Positive surveillance swab cultures (reference negative)</td><td align="center" valign="top" rowspan="1" colspan="1">2.83 (1.37&#x02013;5.87)</td><td align="center" valign="top" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PBSC number (&#x000d7;&#x02009;10<sup>6</sup>/kg)</td><td align="center" valign="top" rowspan="1" colspan="1">0.89 (0.77&#x02013;1.02)</td><td align="center" valign="top" rowspan="1" colspan="1">0.093</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BM number (&#x000d7;&#x02009;10<sup>8</sup>/kg)</td><td align="center" valign="top" rowspan="1" colspan="1">1.01 (0.78&#x02013;1.31)</td><td align="center" valign="top" rowspan="1" colspan="1">0.934</td></tr></tbody></table><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="5" valign="bottom" rowspan="1">5.2 Multivariate</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Model 1</th><th align="center" rowspan="2" valign="bottom" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Model 2</th><th align="center" valign="bottom" rowspan="1" colspan="1"/></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Adjusted hazard ratio (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Adjusted hazard ratio (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">HCT&#x02010;CI</td><td align="center" valign="top" rowspan="1" colspan="1">1.69 (1.12&#x02013;2.55)</td><td align="center" valign="top" rowspan="1" colspan="1">0.012</td><td align="center" valign="top" rowspan="1" colspan="1">1.82 (1.25&#x02013;2.65)</td><td align="center" valign="top" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VRE and/or CRGNB colonization (positive&#x02009;&#x000d7;&#x02009;negative)</td><td align="center" valign="top" rowspan="1" colspan="1">1.67 (0.69&#x02013;4.09)</td><td align="center" valign="top" rowspan="1" colspan="1">0.258</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PBSC number (&#x000d7;&#x02009;10<sup>6</sup>/kg)</td><td align="center" valign="top" rowspan="1" colspan="1">0.86 (0.74&#x02013;1.00)</td><td align="center" valign="top" rowspan="1" colspan="1">0.052</td><td align="center" valign="top" rowspan="1" colspan="1">0.86 (0.74&#x02013;0.99)</td><td align="center" valign="top" rowspan="1" colspan="1">0.039</td></tr></tbody></table><table-wrap-foot id="cam470541-ntgp-0006"><fn id="cam470541-note-0009"><p>
<italic toggle="yes">Note:</italic> Proportional hazards test, test 1 Chi (2)&#x02009;=&#x02009;6.46, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.091, and test 2 Chi (2)&#x02009;=&#x02009;3.21, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.201.</p></fn></table-wrap-foot></table-wrap><p>Among the 57 patients who underwent engraftment, five (8.8%) died before D&#x02009;+&#x02009;100, with a median of 1.6&#x02009;months. Three infections deaths: two patients died from bloodstream <italic toggle="yes">
<styled-content style="fixed-case" toggle="no">Klebsiella pneumoniae</styled-content> carbapenemase</italic> (KPC) infections and were pre&#x02010;transplant infected, one from <italic toggle="yes">Acinetobacter baumani</italic> sepsis, and the other from CMV pulmonary infectious. And two deaths for acute GVHD were associated with Adenovirus infections. After D&#x02009;+&#x02009;100, there were four infection deaths: two for pulmonary sepsis, one for KPC bloodstream, and the last for <italic toggle="yes">Varicella&#x02010;zoster virus</italic> (VZV), Table&#x000a0;<xref rid="cam470541-tbl-0006" ref-type="table">6</xref>. CRGNB was significant in univariate analysis for DFS (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.005) and OS (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.002), Tables&#x000a0;<xref rid="cam470541-tbl-0004" ref-type="table">4</xref> and <xref rid="cam470541-tbl-0005" ref-type="table">5</xref>.</p><table-wrap position="float" id="cam470541-tbl-0006" content-type="TABLE"><label>TABLE 6</label><caption><p>Deaths concerning 100&#x02009;days, excluded engraftment fail.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Between engraftment and 100&#x02009;days</th><th align="center" valign="bottom" rowspan="1" colspan="1">After 100&#x02009;days</th><th align="center" valign="bottom" rowspan="1" colspan="1">Total</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;5/57 (8.8%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;17/57 (29.8%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;22/57 (38.6%)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Age years (range)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">25 [5&#x02013;56]</td><td align="center" valign="top" rowspan="1" colspan="1">25.5 [3&#x02013;66]</td><td align="center" valign="top" rowspan="1" colspan="1">25 [3&#x02013;66]</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">
<bold>Diagnosis</bold>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">AML (<italic toggle="yes">n</italic>&#x02009;=&#x02009;12)</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">7/12 (58.3%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">ALL (<italic toggle="yes">n</italic>&#x02009;=&#x02009;14)</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">7/14 (50%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">CML (<italic toggle="yes">n</italic>&#x02009;=&#x02009;6)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">2/6 (33.3%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">HL (<italic toggle="yes">n</italic>&#x02009;=&#x02009;6)</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">3/6 (50%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">SAA (<italic toggle="yes">n</italic>&#x02009;=&#x02009;9)</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2/9 (22.2%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Sickle cell disease (<italic toggle="yes">n</italic>&#x02009;=&#x02009;5)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1/5 (20%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">NHL, ABL, DCL, CLL, MDS (<italic toggle="yes">n</italic>&#x02009;=&#x02009;1)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">
<bold>Previous colonization</bold>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">CRGNB Pos (<italic toggle="yes">n</italic>&#x02009;=&#x02009;8)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">3/17 (17.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">3/8 (37.5%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">CRGNB Neg (<italic toggle="yes">n</italic>&#x02009;=&#x02009;36)</td><td align="center" valign="top" rowspan="1" colspan="1">2/5 (40%)</td><td align="center" valign="top" rowspan="1" colspan="1">7/17 (41.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">9/36 (25%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">VRE Pos (<italic toggle="yes">n</italic>&#x02009;=&#x02009;03)</td><td align="center" valign="top" rowspan="1" colspan="1">1/5 (20%)</td><td align="center" valign="top" rowspan="1" colspan="1">1/17 (5.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">2/3 (66.7%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">ND (<italic toggle="yes">n</italic>&#x02009;=&#x02009;10)</td><td align="center" valign="top" rowspan="1" colspan="1">2/5 (40%)</td><td align="center" valign="top" rowspan="1" colspan="1">6/17 (35.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">8/10 (80%)</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">
<bold>HCT&#x02010;CI</bold>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">0 (<italic toggle="yes">n</italic>&#x02009;=&#x02009;31)</td><td align="center" valign="top" rowspan="1" colspan="1">1/5 (20%)</td><td align="center" valign="top" rowspan="1" colspan="1">10/17 (58.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">11/31 (35.4%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">1 (<italic toggle="yes">n</italic>&#x02009;=&#x02009;19)</td><td align="center" valign="top" rowspan="1" colspan="1">2/5 (40%)</td><td align="center" valign="top" rowspan="1" colspan="1">6/17 (35.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">8/19 (42.1%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">2 (<italic toggle="yes">n</italic>&#x02009;=&#x02009;4)</td><td align="center" valign="top" rowspan="1" colspan="1">1/5 (20%)</td><td align="center" valign="top" rowspan="1" colspan="1">1/17 (5.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">2/4 (50%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">3 (<italic toggle="yes">n</italic>&#x02009;=&#x02009;1)</td><td align="center" valign="top" rowspan="1" colspan="1">1/5 (20%)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1/1 (100%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">ND (<italic toggle="yes">n</italic>&#x02009;=&#x02009;2)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">
<bold>Conditioning</bold>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">RIC (<italic toggle="yes">n</italic>&#x02009;=&#x02009;51)</td><td align="center" valign="top" rowspan="1" colspan="1">4/5 (80%)</td><td align="center" valign="top" rowspan="1" colspan="1">16/17 (94.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">20/51 (39.2%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">MAC (<italic toggle="yes">n</italic>&#x02009;=&#x02009;6)</td><td align="center" valign="top" rowspan="1" colspan="1">1/5 (20%)</td><td align="center" valign="top" rowspan="1" colspan="1">1/17 (5.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">2/6 (33.3%)</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">
<bold>Cause of death</bold>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Infection</td><td align="center" valign="top" rowspan="1" colspan="1">3/5 (60%)</td><td align="center" valign="top" rowspan="1" colspan="1">4/17 (23.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">7/57 (12.2%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">GvHD</td><td align="center" valign="top" rowspan="1" colspan="1">2/5 (40%)</td><td align="center" valign="top" rowspan="1" colspan="1">2/17 (11.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">4/57 (7%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Relapse<xref rid="cam470541-note-0011" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">11/17 (64.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">11/49 (22.4%)<xref rid="cam470541-note-0011" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr></tbody></table><table-wrap-foot id="cam470541-ntgp-0007"><fn id="cam470541-note-0011"><label>
<sup>a</sup>
</label><p>Evaluated at 49 patients with malignant diseases.</p></fn></table-wrap-foot></table-wrap><p>There was one case of tuberculosis (1.7%). He was transplanted with stable HL and relapsed at 12.6&#x02009;months. Pulmonary tuberculosis was diagnosed at 14&#x02009;months, and there is no more evidence of infection at 18.4&#x02009;months.</p><p>There were five pulmonary invasive Aspergillosis. One after MAC died, and four after RIC were successfully treated. Preemptive treatment for CMV was done in 26/57 (45.6%). There were four (7%) VZV infections; two adenovirus infections (3.5%), and one urinary JC virus with engraftment lost.</p><p>Grades III&#x02013;IV acute GVHD were observed in 12.3% (7/57; 95% CI, 3.8%&#x02013;20.8%), one just after donor lymphocyte infusions (DLI). Two of the seven died of Grade IV acute GVHD on D&#x02009;+&#x02009;48 and D&#x02009;+&#x02009;93. Chronic GVHD was seen in 21.2% (11/52; 95% CI, 10.1%&#x02013;32.3%) transplants after D&#x02009;+&#x02009;100. The extensive form was observed in 3/52 (5.8%). Two extensive chronic GVHD patients died on D&#x02009;+&#x02009;201 and 237, with hepatic and cutaneous involvements. The third patient presented severe sclerotic cutaneous and cholestatic liver injury.</p><p>The Grade II acute GVHD in benign diseases was observed in 4/15 (26.6%) patients. Four of fourteen (28.6%) had moderate GVHD. Grades III&#x02013;IV acute, and severe chronic GVHD were not observed. The 2&#x02010;year OS was 73.3% (95% CI, 51%&#x02013;95.7%), Figure&#x000a0;<xref rid="cam470541-fig-0001" ref-type="fig">1</xref>.</p><fig position="float" fig-type="FIGURE" id="cam470541-fig-0001"><label>FIGURE 1</label><caption><p>Overall Survival for benign diseases. 86.7% at 6&#x02009;months, 86.7% at 12&#x02009;months, and 73.3% at 24&#x02009;months.</p></caption><graphic xlink:href="CAM4-14-e70541-g002" position="anchor" id="jats-graphic-1"/></fig><p>Twelve of the forty&#x02010;nine patients with malignant disease analyzed had relapsed at 24.5% (95% CI, 12.4%&#x02013;36.5%). Ten relapses were acute leukemia, with a median time of 8.1&#x02009;months, four ALL, and six AML. All this relapsed acute leukemia, despite new chemotherapy associated with DLI, had died, and the median survival time was 10.7&#x02009;months (5.7&#x02013;21.6). Two patients with HL relapsed. The first relapsed at 15.2&#x02009;months and died from it at 20.2&#x02009;months, and the other relapsed at 5.2&#x02009;months and is alive with 22.3&#x02009;months of follow&#x02010;up. One patient with MDS had autologous recovery and maintained pancytopenia with a follow&#x02010;up of 33.7&#x02009;months.</p><p>Death concerning 100&#x02009;days was in 5/57 after engraftment (8.8%). After 100&#x02009;days, the death was related to relapse, observed in 64.7% (11/17; 95% CI, 42%&#x02013;87.4%) patients in this period, Table&#x000a0;<xref rid="cam470541-tbl-0006" ref-type="table">6</xref>. No variable was significant in the univariate analysis for relapsed. In malignant patients, the 2&#x02010;year relapse, DFS, and OS were 24.5% (95% CI, 12.4%&#x02013;36.5%), 44.9% (95% CI, 31%&#x02013;58.8%), and 49% (95% CI, 35%&#x02013;63%), respectively. OS at 2 years for benign diseases was 73.3% (95% CI, 51%&#x02013;95.7%), Figures&#x000a0;<xref rid="cam470541-fig-0001" ref-type="fig">1</xref> and <xref rid="cam470541-fig-0002" ref-type="fig">2</xref>. Acute III&#x02013;IV and moderate/severe chronic GVHD were observed in 12.3% (95% CI, 3.8%&#x02013;20.8%) and 21.2% (95% CI, 10.1%&#x02013;32.3%), respectively, Table&#x000a0;<xref rid="cam470541-tbl-0002" ref-type="table">2</xref>.</p><fig position="float" fig-type="FIGURE" id="cam470541-fig-0002"><label>FIGURE 2</label><caption><p>Disease&#x02010;free Survival and Overall Survival for malign diseases. Overall survival: 71.4% at 6&#x02009;months, 54.4% at 12&#x02009;months, and 49% at 24&#x02009;months. Disease&#x02010;free survival: 59.2% at 6&#x02009;months, 48.2% at 12&#x02009;months, and 44.9% at 24&#x02009;months.</p></caption><graphic xlink:href="CAM4-14-e70541-g001" position="anchor" id="jats-graphic-3"/></fig></sec><sec sec-type="discussion" id="cam470541-sec-0009"><label>4</label><title>Discussion</title><p>While the initial Hid&#x02010;HCT with PT&#x02010;Cy regimen employed marrow BM grafts, many centers prefer PBSC. The classical Baltimore's group study with PT&#x02010;Cy with BM source observed graft failure occurred in 9 of 66 (13%) evaluable patients and was fatal in 1. The cumulative incidences of Grades II&#x02013;IV and III&#x02013;IV acute GVHD by Day 200 were 34% and 6%, respectively. There was a trend toward a lower risk of extensive chronic GVHD among recipients of 2 versus 1 dose of PT&#x02010;Cy (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.05), the only difference between these groups. The cumulative incidences of NRM and relapse at 1&#x02009;year were 15% and 51%, respectively. Actuarial OS and EFS 2&#x02010;year after transplantation were 36% and 26%, respectively [<xref rid="cam470541-bib-0006" ref-type="bibr">6</xref>].</p><p>In a prior large prospective study, PBSC has proven to cause a higher risk of chronic GVHD but lower engraftment failure in a population of mostly matched unrelated donor transplants who did not receive PT&#x02010;Cy [<xref rid="cam470541-bib-0024" ref-type="bibr">24</xref>]. Given the impact of PT&#x02010;Cy on lowering chronic GVHD rates, other investigators have evaluated PBSC with PT&#x02010;Cy versus bone marrow transplant with PT&#x02010;Cy. Bashey et&#x000a0;al. compared 681 patients and found that bone marrow source resulted in significantly lower acute GVHD (25% vs. 42%) and chronic GVHD (20% vs. 41%), but higher relapse rates (45% vs. 28%) compared with PBSC. Engraftment, NRM, and OS were similar in the two groups. In subgroup analysis, they confirmed that the difference in relapse rates was found in patients with myeloid diseases but not lymphoma [<xref rid="cam470541-bib-0007" ref-type="bibr">7</xref>]. In a similar study of 86 patients, no differences were found in GVHD rates, but relapse was higher in the marrow group (58% vs. 24%) [<xref rid="cam470541-bib-0026" ref-type="bibr">26</xref>]. Though prospective data are needed, relapse rates may be improved with PBSC, while PT&#x02010;Cy may mitigate the risk of GVHD.</p><p>About the malignant diseases in this analysis, the 2&#x02010;year DFS and OS were 44.9% and 49%, and acute III&#x02013;IV and moderate/severe chronic GVHD were observed in 12.3% and 21.2%, respectively. Xu et&#x000a0;al. demonstrated the superiority of DSC over PBSC in acute leukemias with MAC and ATG. They observed a lower incidence of 2&#x02010;year NRM (62.5%&#x02009;&#x000b1;&#x02009;14.8% vs. 35.1%&#x02009;&#x000b1;&#x02009;5.1%; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.014), higher OS (26.8%&#x02009;&#x000b1;&#x02009;12.3% vs. 43.2%&#x02009;&#x000b1;&#x02009;5.0%; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.052) and DFS (26.8%&#x02009;&#x000b1;&#x02009;12.3% vs. 42.4%&#x02009;&#x000b1;&#x02009;5.0%; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.071), respectively [<xref rid="cam470541-bib-0027" ref-type="bibr">27</xref>]. In 2019, the EBMT compared Hid&#x02010;HCT with RIC or MAC,&#x000a0;in AML patients older than 45&#x02009;years. RIC was performed in 539 patients, with 78% receiving PT&#x02010;Cy, and the source was PBSC in 60.3%. The 2&#x02010;year LFS, OS, acute GVHD III&#x02013;IV, and chronic extensive GVHD were 41%, 44.1%, 10.5%, and 15%, respectively [<xref rid="cam470541-bib-0028" ref-type="bibr">28</xref>].</p><p>In 2016, the EBMT analyzed the intensity of conditioning in Hid&#x02010;HCT using PT&#x02010;Cy for acute leukemia. In patients with RIC, 65% received PBSC and 35% BM. Acute GVHD III&#x02013;IV and chronic GvHD were observed in 10.9% and 24.7%, respectively. The LFS and OS at 2 years for patients in CR1, &#x02265;&#x02009;CR2, and active disease were 38.9% and 46.9%, 24.6% and 29.8%, 11.3% and 14.3%, respectively [<xref rid="cam470541-bib-0029" ref-type="bibr">29</xref>].</p><p>A meta&#x02010;analysis comparing PBSC and BM in Hid&#x02010;HCT with PT&#x02010;Cy in adult patients showed significantly elevated incidences of acute GVHD III&#x02013;IV (OR&#x02009;=&#x02009;1.741, 95% CI 1032&#x02013;2938) and II&#x02013;IV (OR&#x02009;=&#x02009;1778, 95% CI 1314, 2406) and higher engrafting rates (OR&#x02009;=&#x02009;1843, 95% CI 1066&#x02013;3185) in the PBSC group. No significant difference was found in 2&#x02010;year relapse incidence, OS, and DFS. The pooled OS of single&#x02010;arm BM and PB studies were 0.543 and 0.591. The pooled incidence of DFS in BM and PBSC studies were 0.438 and 0.519 [<xref rid="cam470541-bib-0030" ref-type="bibr">30</xref>]. Hid&#x02010;HCT with ATG and DSC achieved similar results as identical allogeneic HCT in acute leukemias, MDS, and SAA [<xref rid="cam470541-bib-0031" ref-type="bibr">31</xref>]. In our group, the number of CD34<sup>+</sup> cells infused with PBSC reduced the risk of disease progression. Maybe this finding&#x000a0;could be explained by the larger number of T&#x02010;lymphocytes on the mobilized PBSC, which can induce a stronger graft&#x02010;versus&#x02010;tumor.</p><p>The Beijing Protocol for non&#x02010;malignant diseases such as SAA showed acute GVHD of 4% and 7.9%, extensive chronic GVHD of 4% and 5%, 3y OS of 84.6% and 89%, and 3y FFS of 84.6% and 86.8%, for adults and children/adolescents, respectively [<xref rid="cam470541-bib-0032" ref-type="bibr">32</xref>, <xref rid="cam470541-bib-0033" ref-type="bibr">33</xref>]. Wang, Y. et&#x000a0;al., in 756 Hid&#x02010;HCT with malignant and benign diseases using the Beijing Protocol, the 3&#x02010;year cumulative NRM was 18%, the 3&#x02010;year LFS was 68%, and 49% for low&#x02010;risk and high&#x02010;risk patients, respectively [<xref rid="cam470541-bib-0034" ref-type="bibr">34</xref>]. DeZern, A. E. et&#x000a0;al. added ATG to the classic Baltimore Protocol for SAA in 37 patients and BM source. The cumulative incidence of grade II&#x02010;IV acute GVHD at Day 100 was 11%. The cumulative index of 2&#x02010;year chronic GVHD was 8% [<xref rid="cam470541-bib-0035" ref-type="bibr">35</xref>].</p><p>HCT&#x02010;CI&#x02009;&#x02265;&#x02009;2 was observed in 33.7% and 17% of patients in two Brazilian publications of <italic toggle="yes">Sistema &#x000da;nico de Sa&#x000fa;de</italic> (SUS) patients [<xref rid="cam470541-bib-0036" ref-type="bibr">36</xref>, <xref rid="cam470541-bib-0037" ref-type="bibr">37</xref>]. In this survey, an HCT&#x02010;CI&#x02009;&#x02265;&#x02009;2 was observed in 12.5% of the transplants and increased the death risk. In an analysis in four French centers with 223 patients, the impact of HCT&#x02010;CI in Hid&#x02010;HCT and PT&#x02010;Cy, with PBSC (<italic toggle="yes">n</italic>&#x02009;=&#x02009;207) or BM (<italic toggle="yes">n</italic>&#x02009;=&#x02009;8), did not observe statistical significance [<xref rid="cam470541-bib-0038" ref-type="bibr">38</xref>]. This study sample size was small to analyze OS for DRI. Although for Hid&#x02010;HCT, NMA with PT&#x02010;Cy, McCurdy, et&#x000a0;al. observed three&#x02010;year OS 71%, 48%, and 35%, for low, intermediate, and high/very high risk, respectively [<xref rid="cam470541-bib-0039" ref-type="bibr">39</xref>].</p><p>Infection&#x02010;related mortality (IRM) was observed in 35% of cases in the series of 3394 allogeneic HCT in 2705 adults and 689 pediatrics in the Australian Registry, between 2013 and 2018. In adults, IRM was worse in the elderly, use of ATG or alemtuzumab, CMV serology positive in donor and negative recipient, and acute GVHD. In children, the risk was higher for ALL, unrelated to mismatch, and Hid&#x02010;HCT. Bacterial etiology was responsible for 49.3% of IRM in adults and the virus for 45% in children [<xref rid="cam470541-bib-0040" ref-type="bibr">40</xref>]. The <italic toggle="yes">Grupo Espa&#x000f1;ol de Trasplante Hematopoy&#x000e9;tico</italic>, in 236 Hid&#x02010;HCT, observed a 3&#x02010;year IRM of 19%. CMV infection was 69%. All these patients received PT&#x02010;Cy, 68% received RIC, and 32% MAC, 81% received PBSC, and 19% BM. IRM risk factors for IRM were age over 50&#x02009;years, lymphoid neoplasms, and GVHD III&#x02010;IV. The etiology of the IRM was bacterial in 51%, most of them Gram&#x02010;negative bacteria [<xref rid="cam470541-bib-0041" ref-type="bibr">41</xref>]. In these two publications, from Australian and Spanish groups, infections and colonization before transplants are not analyzed.</p><p>In our series, there were 13 deaths due to bacterial infection, six before and seven after engraftment, in the 64 Hid&#x02010;HCT performed (20.3%). It is worth noting that 31.5% of the patients were colonized by CRGNB and/or VRE. Colonization of patients by CRGNB led to early mortality that compromised the engraftment. It is important to note that in Brazil, the ceftazidime/avibactam approval of use occurred in June 2018. During the study time, the drug was not available in these institutions. Comparing the results observed with IRM in the literature, we can suggest a benefit with the use of DSC in Hid&#x02010;HCT with PT&#x02010;Cy, despite the quantitative limitation of our series, the lack of population data on colonization, and previous infections in these other studies. It is necessary to highlight the prior swabs to assess colonization by resistant bacteria. CRGNB was significant in univariate analysis for DFS. CMV infection was 45.6%, comparable to the results observed in the cited publications. The CIBMTR analyzing Hid&#x02010;HCT with PT&#x02010;Cy from 2012 to 2017 observed 42% CMV infection. In identical allogeneic HCT use of PT&#x02010;Cy, there were also more infections than allogeneic without PT&#x02010;Cy, 37% and 23%, respectively. PT&#x02010;Cy, regardless of the donor, was associated with a higher incidence of CMV infection, increasing the risk of seropositivity, regardless of the donor [<xref rid="cam470541-bib-0042" ref-type="bibr">42</xref>].</p></sec><sec sec-type="conclusions" id="cam470541-sec-0010"><label>5</label><title>Conclusion</title><p>The results observed with DSC and PT&#x02010;Cy in Hid&#x02010;HCT in this group of patients are difficult to compare with previous publications. An interesting view in this survey was the HCT&#x02010;CI that predicted DFS and OS. The characteristics of the analyzed population, infectious data, and conditioning intensity are preliminary for further studies to consolidate the results.</p></sec><sec id="cam470541-sec-0011"><title>Author Contributions</title><p>
<bold>Ana Marcela Rojas Fonseca&#x02010;Hial:</bold> data curation (lead), formal analysis (lead), investigation (lead), methodology (equal), project administration (equal), resources (equal), supervision (equal), validation (equal), visualization (equal), writing &#x02013; original draft (lead), writing &#x02013; review and editing (lead). <bold>Katya Parisio:</bold> data curation (supporting), formal analysis (equal), validation (equal). <bold>Jose Salvador Rodrigues de Oliveira:</bold> conceptualization (lead), data curation (equal), formal analysis (equal), investigation (lead), methodology (lead), project administration (lead), resources (lead), supervision (lead), validation (lead), visualization (equal), writing &#x02013; original draft (equal), writing &#x02013; review and editing (lead).</p></sec><sec sec-type="conclusions" id="cam470541-sec-0012"><title>Consent</title><p>Because of the retrospective and anonymous character of this study, the need for informed consent was waived by the institutional review board and was granted by the &#x0201c;<italic toggle="yes">Federal University of Sao Paulo Ethics Committee</italic>&#x0201d; for this purpose.</p></sec><sec sec-type="COI-statement" id="cam470541-sec-0013"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec></body><back><sec sec-type="data-availability" id="cam470541-sec-0015"><title>Data Availability Statement</title><p>The authors confirm that the data supporting the findings of this study are available from the corresponding author, upon reasonable request due to privacy/ethical restrictions.</p></sec><ref-list content-type="cited-references" id="cam470541-bibl-0001"><title>References</title><ref id="cam470541-bib-0001"><label>1</label><mixed-citation publication-type="miscellaneous" id="cam470541-cit-0001">
<string-name>
<given-names>Y. T.</given-names>
<surname>Bolon</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Atshan</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Allbee&#x02010;Johnson</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Estrada&#x02010;Merly</surname>
</string-name>, <string-name>
<given-names>S. J.</given-names>
<surname>Lee</surname>
</string-name>, and <collab collab-type="authors">CIBMTR</collab>
, <article-title>&#x0201c;Current Use and Outcome of Hematopoietic Stem Cell Transplantation: CIBMTR Summary Slides,&#x0201d;</article-title>
<year>2022</year>, <ext-link xlink:href="https://cibmtr.org/CIBMTR/Resources/Summary-Slides-Reports" ext-link-type="uri">https://cibmtr.org/CIBMTR/Resources/Summary&#x02010;Slides&#x02010;Reports</ext-link>.</mixed-citation></ref><ref id="cam470541-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cam470541-cit-0002">
<string-name>
<given-names>X. J.</given-names>
<surname>Huang</surname>
</string-name>, <string-name>
<given-names>D. H.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>K. Y.</given-names>
<surname>Liu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Haploidentical Hematopoietic Stem Cell Transplantation Without In&#x000a0;Vitro T&#x02010;Cell Depletion for the Treatment of Hematological Malignancies</article-title>,&#x0201d; <source>Bone Marrow Transplantation</source>
<volume>38</volume>, no. <issue>4</issue> (<year>2006</year>): <fpage>291</fpage>&#x02013;<lpage>297</lpage>.<pub-id pub-id-type="pmid">16883312</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cam470541-cit-0003">
<string-name>
<given-names>L.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Chen</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The Consensus on Indications, Conditioning Regimen, and Donor Selection of Allogeneic Hematopoietic Cell Transplantation for Hematological Diseases in China&#x02014;Recommendations From the Chinese Society of Hematology</article-title>,&#x0201d; <source>Journal of Hematology &#x00026; Oncology</source>
<volume>11</volume>, no. <issue>1</issue> (<year>2018</year>): <fpage>33</fpage>.<pub-id pub-id-type="pmid">29495966</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cam470541-cit-0004">
<string-name>
<given-names>X.</given-names>
<surname>Zhao</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Gao</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Zhang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Improved Clinical Outcomes of rhG&#x02010;CSF&#x02010;Mobilized Blood and Marrow Haploidentical Transplantation Compared to Propensity Score&#x02010;Matched rhG&#x02010;CSF&#x02010;Primed Peripheral Blood Stem Cell Haploidentical Transplantation: A Multicenter Study</article-title>,&#x0201d; <source>Science China. Life Sciences</source>
<volume>59</volume>, no. <issue>11</issue> (<year>2016</year>): <fpage>1139</fpage>&#x02013;<lpage>1148</lpage>.<pub-id pub-id-type="pmid">27535422</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cam470541-cit-0005">
<string-name>
<given-names>Y.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>Q. F.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>L. P.</given-names>
<surname>Xu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Haploidentical vs Identical&#x02010;Sibling Transplant for AML in Remission: A Multicenter, Prospective Study</article-title>,&#x0201d; <source>Blood</source>
<volume>125</volume>, no. <issue>25</issue> (<year>2015</year>): <fpage>3956</fpage>&#x02013;<lpage>3962</lpage>.<pub-id pub-id-type="pmid">25940714</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cam470541-cit-0006">
<string-name>
<given-names>L.</given-names>
<surname>Luznik</surname>
</string-name>, <string-name>
<given-names>P. V. O.</given-names>
<surname>Donnell</surname>
</string-name>, <string-name>
<given-names>H. J.</given-names>
<surname>Symons</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>HLA&#x02010;Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High&#x02010;Dose, Posttransplantation Cycliphosphamide</article-title>,&#x0201d; <source>Biology of Blood and Marrow Transplantation</source>
<volume>14</volume>, no. <issue>6</issue> (<year>2008</year>): <fpage>641</fpage>&#x02013;<lpage>650</lpage>.<pub-id pub-id-type="pmid">18489989</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cam470541-cit-0007">
<string-name>
<given-names>A.</given-names>
<surname>Bashey</surname>
</string-name>, <string-name>
<given-names>M. J.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>S. R.</given-names>
<surname>McCurdy</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow as a Graft Source for T&#x02010;Cell&#x02013;Replete Haploidentical Donor Transplantation Using Post&#x02010;Transplant Cyclophosphamide</article-title>,&#x0201d; <source>Journal of Clinical Oncology</source>
<volume>35</volume>, no. <issue>26</issue> (<year>2017</year>): <fpage>3002</fpage>&#x02013;<lpage>3009</lpage>.<pub-id pub-id-type="pmid">28644773</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cam470541-cit-0008">
<string-name>
<given-names>J.</given-names>
<surname>Bola&#x000f1;os&#x02010;Meade</surname>
</string-name>, <string-name>
<given-names>E. J.</given-names>
<surname>Fuchs</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Luznik</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>HLA&#x02010;Haploidentical Bone Marrow Transplantation With Posttransplant Cyclophosphamide Expands the Donor Pool for Patients With Sickle Cell Disease</article-title>,&#x0201d; <source>Blood</source>
<volume>120</volume>, no. <issue>22</issue> (<year>2012</year>): <fpage>4258</fpage>&#x02013;<lpage>4291</lpage>, <ext-link xlink:href="http://www.bloodjournal.org" ext-link-type="uri">www.bloodjournal.org</ext-link>.</mixed-citation></ref><ref id="cam470541-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cam470541-cit-0009">
<string-name>
<given-names>S. P.</given-names>
<surname>Hammond</surname>
</string-name> and <string-name>
<given-names>L. R.</given-names>
<surname>Baden</surname>
</string-name>, &#x0201c;<article-title>Antibiotic Prophylaxis for Patients With Acute Leukemia</article-title>,&#x0201d; <source>Leukemia &#x00026; Lymphoma</source>
<volume>49</volume>, no. <issue>2</issue> (<year>2008</year>): <fpage>183</fpage>&#x02013;<lpage>193</lpage>.<pub-id pub-id-type="pmid">18231904</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cam470541-cit-0010">
<string-name>
<given-names>W. T.</given-names>
<surname>Hughes</surname>
</string-name>, <string-name>
<given-names>G. K.</given-names>
<surname>Rivera</surname>
</string-name>, <string-name>
<given-names>M. J.</given-names>
<surname>Schell</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Thornton</surname>
</string-name>, and <string-name>
<given-names>L.</given-names>
<surname>Lott</surname>
</string-name>, &#x0201c;<article-title>Successful Intermittent Chemoprophylaxis for Pneumocystis Carinii Pneumonitis</article-title>,&#x0201d; <source>New England Journal of Medicine</source>
<volume>316</volume>, no. <issue>26</issue> (<year>1989</year>): <fpage>1627</fpage>&#x02013;<lpage>1632</lpage>.</mixed-citation></ref><ref id="cam470541-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cam470541-cit-0011">
<string-name>
<given-names>M.</given-names>
<surname>Boeckh</surname>
</string-name>, <string-name>
<given-names>H. W.</given-names>
<surname>Kim</surname>
</string-name>, <string-name>
<given-names>M. E. D.</given-names>
<surname>Flowers</surname>
</string-name>, <string-name>
<given-names>J. D.</given-names>
<surname>Meyers</surname>
</string-name>, and <string-name>
<given-names>R. A.</given-names>
<surname>Bowden</surname>
</string-name>, &#x0201c;<article-title>Long&#x02010;Term Acyclovir for Prevention of Varicella Zoster Virus Disease After Allogeneic Hematopoietic Cell Transplantation&#x02014;A Randomized Double&#x02010;Blind Placebo&#x02010;Controlled Study</article-title>,&#x0201d; <source>Blood</source>
<volume>107</volume>, no. <issue>5</issue> (<year>2006</year>): <fpage>1800</fpage>&#x02013;<lpage>1805</lpage>.<pub-id pub-id-type="pmid">16282339</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cam470541-cit-0012">
<string-name>
<given-names>K. A.</given-names>
<surname>Marr</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Seidel</surname>
</string-name>, <string-name>
<given-names>M. A.</given-names>
<surname>Slavin</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Prolonged Fluconazole Prophylaxis Is Associated With Persistent Protection Against Candidiasis&#x02010;Related Death in Allogeneic Marrow Transplant Recipients: Long&#x02010;Term Follow&#x02010;Up of a Randomized, Placebo&#x02010;Controlled Trial</article-title>,&#x0201d; <source>Blood</source>
<volume>96</volume>, no. <issue>6</issue> (<year>2000</year>): <fpage>2055</fpage>&#x02013;<lpage>2061</lpage>, <pub-id pub-id-type="doi">10.1182/blood.V96.6.2055</pub-id>.<pub-id pub-id-type="pmid">10979947</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cam470541-cit-0013">
<string-name>
<given-names>P.</given-names>
<surname>Armand</surname>
</string-name>, <string-name>
<given-names>H. T.</given-names>
<surname>Kim</surname>
</string-name>, <string-name>
<given-names>B. R.</given-names>
<surname>Logan</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Validation and Refinement of the Disease Risk Index for Allogeneic Stem Cell Transplantation</article-title>,&#x0201d; <source>Blood</source>
<volume>123</volume>, no. <issue>23</issue> (<year>2014</year>): <fpage>3664</fpage>&#x02013;<lpage>3671</lpage>.<pub-id pub-id-type="pmid">24744269</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cam470541-cit-0014">
<string-name>
<given-names>J. W.</given-names>
<surname>Kim</surname>
</string-name>, <string-name>
<given-names>H. J.</given-names>
<surname>Lee</surname>
</string-name>, <string-name>
<given-names>H. G.</given-names>
<surname>Yi</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Mitoxantrone, Etoposide, Cytarabine, and Melphalan (NEAM) Followed by Autologous Stem Cell Transplantation for Patients With Chemosensitive Aggressive Non&#x02010;Hodgkin Lymphoma</article-title>,&#x0201d; <source>American Journal of Hematology</source>
<volume>87</volume>, no. <issue>5</issue> (<year>2012</year>): <fpage>479</fpage>&#x02013;<lpage>483</lpage>.<pub-id pub-id-type="pmid">22388671</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cam470541-cit-0015">
<string-name>
<given-names>S. R.</given-names>
<surname>Solomon</surname>
</string-name>, <string-name>
<given-names>C. A.</given-names>
<surname>Sizemore</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Sanacore</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients With High&#x02010;Risk Hematologic Malignancies Who Lack Conventional Donors Is Well Tolerated and Produces Excellent Relapse&#x02010;Free Survival: Results of a Prospective Phase II Trial</article-title>,&#x0201d; <source>Biology of Blood and Marrow Transplantation</source>
<volume>18</volume>, no. <issue>12</issue> (<year>2012</year>): <fpage>1859</fpage>&#x02013;<lpage>1866</lpage>.<pub-id pub-id-type="pmid">22863841</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cam470541-cit-0016">
<string-name>
<given-names>P. J.</given-names>
<surname>Tutschka</surname>
</string-name>, <string-name>
<given-names>E. A.</given-names>
<surname>Copelan</surname>
</string-name>, and <string-name>
<given-names>J. P.</given-names>
<surname>Klein</surname>
</string-name>, &#x0201c;<article-title>Bone Marrow Transplantation for Leukemia Following a New Busulfan and Cyclophosphamide Regimen</article-title>,&#x0201d; <source>Blood</source>
<volume>70</volume>, no. <issue>5</issue> (<year>1987</year>): <fpage>1382</fpage>&#x02013;<lpage>1388</lpage>.<pub-id pub-id-type="pmid">3311203</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cam470541-cit-0017">
<string-name>
<given-names>A. M.</given-names>
<surname>Raiola</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Dominietto</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Ghiso</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Unmanipulated Haploidentical Bone Marrow Transplantation and Posttransplantation Cyclophosphamide for Hematologic Malignancies After Myeloablative Conditioning</article-title>,&#x0201d; <source>Biology of Blood and Marrow Transplantation</source>
<volume>19</volume>, no. <issue>1</issue> (<year>2013</year>): <fpage>117</fpage>&#x02013;<lpage>122</lpage>.<pub-id pub-id-type="pmid">22940057</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cam470541-cit-0018">
<string-name>
<given-names>A.</given-names>
<surname>Bacigalupo</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Dominietto</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Ghiso</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Unmanipulated Haploidentical Bone Marrow Transplantation and Post&#x02010;Transplant Cyclophosphamide for Hematologic Malignanices Following a Myeloablative Conditioning: An Update</article-title>,&#x0201d; <source>Bone Marrow Transplantation</source>
<volume>50</volume>, no. <issue>Suppl 2</issue> (<year>2015</year>): <fpage>S37</fpage>&#x02013;<lpage>S39</lpage>.<pub-id pub-id-type="pmid">26039205</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cam470541-cit-0019">
<string-name>
<given-names>C. G.</given-names>
<surname>Kanakry</surname>
</string-name>, <string-name>
<given-names>P. V.</given-names>
<surname>O'Donnell</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Furlong</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Multi&#x02010;Institutional Study of Post&#x02010;Transplantation Cyclophosphamide as Single&#x02010;Agent Graft&#x02010;Versus&#x02010;Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning</article-title>,&#x0201d; <source>Journal of Clinical Oncology</source>
<volume>32</volume>, no. <issue>31</issue> (<year>2014</year>): <fpage>3497</fpage>&#x02013;<lpage>3505</lpage>.<pub-id pub-id-type="pmid">25267759</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cam470541-cit-0020">
<string-name>
<given-names>T.</given-names>
<surname>Pagliardini</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Castagna</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Harbi</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Thiotepa, Fludarabine, and Busulfan Conditioning Regimen Before T Cell&#x02013;Replete Haploidentical Transplantation With Post&#x02010;Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients</article-title>,&#x0201d; <source>Biology of Blood and Marrow Transplantation</source>
<volume>25</volume>, no. <issue>9</issue> (<year>2019</year>): <fpage>1803</fpage>&#x02013;<lpage>1809</lpage>.<pub-id pub-id-type="pmid">31128325</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="cam470541-cit-0021">
<string-name>
<given-names>S. S.</given-names>
<surname>Rohr</surname>
</string-name>, <string-name>
<given-names>R. C.</given-names>
<surname>Maranh&#x000e3;o</surname>
</string-name>, <string-name>
<given-names>T. M.</given-names>
<surname>Tavoni</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Novel Approach for Bone Marrow Transplantation Conditioning in Acute Myelogenous Leukemia Not Responding to the Induction Therapy Using Etoposide Carried in Lipid Core Nanoparticles: A Pilot Clinical Study</article-title>,&#x0201d; <source>Biology of Blood and Marrow Transplantation</source>
<volume>26</volume>, no. <issue>11</issue> (<year>2020</year>): <fpage>2027</fpage>&#x02013;<lpage>2033</lpage>.<pub-id pub-id-type="pmid">32682949</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="cam470541-cit-0022">
<string-name>
<given-names>M. L.</given-names>
<surname>Sorror</surname>
</string-name>, <string-name>
<given-names>M. B.</given-names>
<surname>Maris</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Storb</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Hematopoietic Cell Transplantation (HCT)&#x02010;specific Comorbidity Index: A New Tool for Risk Assessment Before Allogeneic HCT</article-title>,&#x0201d; <source>Blood</source>
<volume>106</volume>, no. <issue>8</issue> (<year>2005</year>): <fpage>2912</fpage>&#x02013;<lpage>2919</lpage>.<pub-id pub-id-type="pmid">15994282</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cam470541-cit-0023">
<string-name>
<given-names>M. L.</given-names>
<surname>Sorror</surname>
</string-name>, &#x0201c;<article-title>Comorbidities and Hematopoietic Cell Transplantation Outcomes</article-title>,&#x0201d; <source>Hematology. American Society of Hematology. Education Program</source> (<year>2010</year>): <fpage>237</fpage>&#x02013;<lpage>247</lpage>, <pub-id pub-id-type="doi">10.1182/asheducation-2010.1.237</pub-id>.<pub-id pub-id-type="pmid">21239800</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="cam470541-cit-0024">
<string-name>
<given-names>C.</given-names>
<surname>Anasetti</surname>
</string-name>, <string-name>
<given-names>B. R.</given-names>
<surname>Logan</surname>
</string-name>, <string-name>
<given-names>S. J.</given-names>
<surname>Lee</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Peripheral&#x02010;Blood Stem Cells Versus Bone Marrow From Unrelated Donors</article-title>,&#x0201d; <source>New England Journal of Medicine</source>
<volume>367</volume>, no. <issue>16</issue> (<year>2012</year>): <fpage>1487</fpage>&#x02013;<lpage>1496</lpage>.<pub-id pub-id-type="pmid">23075175</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="cam470541-cit-0025">
<string-name>
<given-names>V.</given-names>
<surname>Dhere</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Edelman</surname>
</string-name>, <string-name>
<given-names>E. K.</given-names>
<surname>Waller</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Myeloablative Busulfan/Cytoxan Conditioning Versus Reduced&#x02010; Intensity Fludarabine/Melphalan Conditioning for Allogeneic Hematopoietic Stem Cell Transplant in Patients With Acute Myelogenous Leukemia</article-title>,&#x0201d; <source>Leukemia &#x00026; Lymphoma</source>
<volume>59</volume>, no. <issue>4</issue> (<year>2018</year>): <fpage>837</fpage>&#x02013;<lpage>843</lpage>.<pub-id pub-id-type="pmid">28782395</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="cam470541-cit-0026">
<string-name>
<given-names>P. V.</given-names>
<surname>O'Donnell</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Eapen</surname>
</string-name>, <string-name>
<given-names>M. M.</given-names>
<surname>Horowitz</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Comparable Outcomes With Marrow or Peripheral Blood as Stem Cell Sources for Hematopoietic Cell Transplantation From Haploidentical Donors After Non&#x02010;ablative Conditioning: A Matched&#x02010;Pair Analysis</article-title>,&#x0201d; <source>Bone Marrow Transplantation</source>
<volume>51</volume> (<year>2016</year>): <fpage>1599</fpage>&#x02013;<lpage>1601</lpage>.<pub-id pub-id-type="pmid">27526284</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="cam470541-cit-0027">
<string-name>
<given-names>L. P.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>K. Y.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>D. H.</given-names>
<surname>Liu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The Inferiority of G&#x02010;PB to rhG&#x02010;CSF&#x02010;Mobilized Blood and Marrow Grafts as a Stem Cell Source in Patients With High&#x02010;Risk Acute Leukemia Who Underwent Unmanipulated HLA&#x02010;Mismatched/Haploidentical Transplantation: A Comparative Analysis</article-title>,&#x0201d; <source>Bone Marrow Transplantation</source>
<volume>45</volume>, no. <issue>6</issue> (<year>2010</year>): <fpage>985</fpage>&#x02013;<lpage>992</lpage>.<pub-id pub-id-type="pmid">19898505</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="cam470541-cit-0028">
<string-name>
<given-names>N.</given-names>
<surname>Santoro</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Labopin</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Ciceri</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Impact of Conditioning Intensity on Outcomes of Haploidentical Stem Cell Transplantation for Patients With Acute Myeloid Leukemia 45&#x02009;Years of Age and Over</article-title>,&#x0201d; <source>Cancer</source>
<volume>125</volume>, no. <issue>9</issue> (<year>2019</year>): <fpage>1499</fpage>&#x02013;<lpage>1506</lpage>.<pub-id pub-id-type="pmid">30620383</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="cam470541-cit-0029">
<string-name>
<given-names>M. T.</given-names>
<surname>Rubio</surname>
</string-name>, <string-name>
<given-names>B. N.</given-names>
<surname>Savani</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Labopin</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Impact of Conditioning Intensity in T&#x02010;Replete Haplo&#x02010;Identical Stem Cell Transplantation for Acute Leukemia: A Report From the Acute Leukemia Working Party of the EBMT</article-title>,&#x0201d; <source>Journal of Hematology &#x00026; Oncology</source>
<volume>9</volume>, no. <issue>1</issue> (<year>2016</year>): <fpage>25</fpage>.<pub-id pub-id-type="pmid">26980295</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="cam470541-cit-0030">
<string-name>
<given-names>X.</given-names>
<surname>Yu</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Xie</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Bone Marrow Versus Peripheral Blood as a Graft Source for Haploidentical Donor Transplantation in Adults Using Post&#x02010;Transplant Cyclophosphamide&#x02014;A Systematic Review and Meta&#x02010;Analysis</article-title>,&#x0201d; <source>Critical Reviews in Oncology/Hematology</source>
<volume>133</volume> (<year>2019</year>): <fpage>120</fpage>&#x02013;<lpage>128</lpage>.<pub-id pub-id-type="pmid">30661648</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="cam470541-cit-0031">
<string-name>
<given-names>L. P.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>D. P.</given-names>
<surname>Wu</surname>
</string-name>, <string-name>
<given-names>M. Z.</given-names>
<surname>Han</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>A Review of Hematopoietic Cell Transplantation in China: Data and Trends During 2008&#x02013;2016</article-title>,&#x0201d; <source>Bone Marrow Transplantation</source>
<volume>52</volume>, no. <issue>11</issue> (<year>2017</year>): <fpage>1512</fpage>&#x02013;<lpage>1518</lpage>.<pub-id pub-id-type="pmid">28436973</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="cam470541-cit-0032">
<string-name>
<given-names>L.</given-names>
<surname>Gao</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Zhang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Long&#x02010;Term Outcome of HLA&#x02010;Haploidentical Hematopoietic SCT Without In&#x000a0;Vitro T&#x02010;Cell Depletion for Adult Severe Aplastic Anemia After Modified Conditioning and Supportive Therapy</article-title>,&#x0201d; <source>Bone Marrow Transplantation</source>
<volume>49</volume>, no. <issue>4</issue> (<year>2014</year>): <fpage>519</fpage>&#x02013;<lpage>524</lpage>.<pub-id pub-id-type="pmid">24464145</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="cam470541-cit-0033">
<string-name>
<given-names>L. P.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>S. Q.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>D. P.</given-names>
<surname>Wu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Haplo&#x02010;Identical Transplantation for Acquired Severe Aplastic Anaemia in a Multicentre Prospective Study</article-title>,&#x0201d; <source>British Journal of Haematology</source>
<volume>175</volume>, no. <issue>2</issue> (<year>2016</year>): <fpage>265</fpage>&#x02013;<lpage>274</lpage>.<pub-id pub-id-type="pmid">27352174</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="cam470541-cit-0034">
<string-name>
<given-names>Y.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>D. H.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>K. Y.</given-names>
<surname>Liu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Long&#x02010;Term Follow&#x02010;Up of Haploidentical Hematopoietic Stem Cell Transplantation Without In&#x000a0;Vitro T Cell Depletion for the Treatment of Leukemia: Nine Years of Experience at a Single Center</article-title>,&#x0201d; <source>Cancer</source>
<volume>119</volume>, no. <issue>5</issue> (<year>2013</year>): <fpage>978</fpage>&#x02013;<lpage>985</lpage>.<pub-id pub-id-type="pmid">23097265</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="cam470541-cit-0035">
<string-name>
<given-names>A. E.</given-names>
<surname>DeZern</surname>
</string-name>, <string-name>
<given-names>M. L.</given-names>
<surname>Zahurak</surname>
</string-name>, <string-name>
<given-names>H. J.</given-names>
<surname>Symons</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Haploidentical BMT for Severe Aplastic Anemia With Intensive GVHD Prophylaxis Including Posttransplant Cyclophosphamide</article-title>,&#x0201d; <source>Blood Advances</source>
<volume>4</volume>, no. <issue>8</issue> (<year>2020</year>): <fpage>1770</fpage>&#x02013;<lpage>1779</lpage>.<pub-id pub-id-type="pmid">32343796</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="cam470541-cit-0036">
<string-name>
<given-names>C.</given-names>
<surname>Costa&#x02010;Lima</surname>
</string-name>, <string-name>
<given-names>E. C. M.</given-names>
<surname>Miranda</surname>
</string-name>, <string-name>
<given-names>M. P.</given-names>
<surname>Colella</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Pretransplant &#x003b2;2&#x02010;Microglobulin Is Associated With the Risk of Acute Graft&#x02010;Versus&#x02010;Host&#x02010;Disease After Allogeneic Hematopoietic Cell Transplant</article-title>,&#x0201d; <source>Biology of Blood and Marrow Transplantation</source>
<volume>22</volume>, no. <issue>7</issue> (<year>2016</year>): <fpage>1329</fpage>&#x02013;<lpage>1332</lpage>.<pub-id pub-id-type="pmid">27044906</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="cam470541-cit-0037">
<string-name>
<given-names>G. M.</given-names>
<surname>Teixeira</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Bittencourt</surname>
</string-name>, <string-name>
<given-names>A. V.</given-names>
<surname>De Macedo</surname>
</string-name>, <string-name>
<given-names>G. H.</given-names>
<surname>Martinho</surname>
</string-name>, <string-name>
<given-names>E. A.</given-names>
<surname>Colosimo</surname>
</string-name>, and <string-name>
<given-names>S. M.</given-names>
<surname>Rezende</surname>
</string-name>, &#x0201c;<article-title>Assessing the Influence of Different Comorbidities Indexes on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in a Developing Country</article-title>,&#x0201d; <source>PLoS One</source>
<volume>10</volume>, no. <issue>9</issue> (<year>2015</year>): <elocation-id>e0137390</elocation-id>.<pub-id pub-id-type="pmid">26394228</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="cam470541-cit-0038">
<string-name>
<given-names>M.</given-names>
<surname>Jullien</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Orvain</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Berceanu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Impact of Allogeneic Stem Cell Transplantation Comorbidity Indexes After Haplotransplant Using Post&#x02010;Transplant Cyclophosphamide</article-title>,&#x0201d; <source>Cancer Medicine</source>
<volume>10</volume>, no. <issue>20</issue> (<year>2021</year>): <fpage>7194</fpage>&#x02013;<lpage>7202</lpage>.<pub-id pub-id-type="pmid">34547182</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="cam470541-cit-0039">
<string-name>
<given-names>S. R.</given-names>
<surname>Mccurdy</surname>
</string-name>, <string-name>
<given-names>J. A.</given-names>
<surname>Kanakry</surname>
</string-name>, <string-name>
<given-names>M. M.</given-names>
<surname>Showel</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Risk&#x02010;Stratified Outcomes of Nonmyeloablative HLA&#x02010;Haploidentical BMT With High&#x02010;Dose Posttransplantation Cyclophosphamide Key Points</article-title>,&#x0201d; <source>Blood</source>
<volume>125</volume> (<year>2015</year>): <fpage>3024</fpage>&#x02013;<lpage>3031</lpage>.<pub-id pub-id-type="pmid">25814532</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="cam470541-cit-0040">
<string-name>
<given-names>J.</given-names>
<surname>Lindsay</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Kerridge</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Wilcox</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Infection&#x02010;Related Mortality in Adults and Children Undergoing Allogeneic Hematopoietic Cell Transplantation: An Australian Registry Report</article-title>,&#x0201d; <source>Transplantation and Cellular Therapy</source>
<volume>27</volume>, no. <issue>9</issue> (<year>2021</year>): <fpage>798</fpage>, <pub-id pub-id-type="doi">10.1016/j.jtct.2021.05.028</pub-id>.</mixed-citation></ref><ref id="cam470541-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="cam470541-cit-0041">
<string-name>
<given-names>A.</given-names>
<surname>Esquirol</surname>
</string-name>, <string-name>
<given-names>M. J.</given-names>
<surname>Pascual</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Kwon</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Severe Infections and Infection&#x02010;Related Mortality in a Large Series of Haploidentical Hematopoietic Stem Cell Transplantation With Post&#x02010;Transplant Cyclophosphamide</article-title>,&#x0201d; <source>Bone Marrow Transplantation</source>
<volume>56</volume>, no. <issue>10</issue> (<year>2021</year>): <fpage>2432</fpage>&#x02013;<lpage>2444</lpage>.<pub-id pub-id-type="pmid">34059802</pub-id>
</mixed-citation></ref><ref id="cam470541-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="cam470541-cit-0042">
<string-name>
<given-names>S. R.</given-names>
<surname>Goldsmith</surname>
</string-name>, <string-name>
<given-names>M. B.</given-names>
<surname>Abid</surname>
</string-name>, <string-name>
<given-names>J. J.</given-names>
<surname>Auletta</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Posttransplant Cyclophosphamide Is Associated With Increased Cytomegalovirus Infection: A CIBMTR Analysis</article-title>,&#x0201d; <source>Blood</source>
<volume>137</volume>, no. <issue>23</issue> (<year>2021</year>): <fpage>3291</fpage>&#x02013;<lpage>3305</lpage>, <pub-id pub-id-type="doi">10.1182/blood.2020009362</pub-id>.<pub-id pub-id-type="pmid">33657221</pub-id>
</mixed-citation></ref></ref-list></back></article>